JNK
信号通路图
研究领域
抑制剂选择性比较
JNK产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1460 |
SP600125SP600125是一种广谱JNK抑制剂，作用于JNK1，JNK2和JNK3，无细胞试验中IC50分别为40 nM，40 nM和90 nM，比作用于MKK4选择性高10倍，比作用于MKK3， MKK6， PKB，和PKCα选择性高25倍，比作用于ERK2， p38， Chk1， EGFR等选择性高100倍。 |
Loss of DUSP4 function upregulates IL-6 and IL-8 and enhances mammosphere growth. Immunoblot analysis of MDA-231 cells after treatment of 24 hours with 1 umol/L selumetinib (MEKi) or 10 umol/L SP600125 (JNKi). I, MDA-231 mammosphere formation quantitated by GelCount software 7 days after siRNA transfection. Where indicated, selumetinib (MEKi) or SP600125 (JNK1) or the combination was added to the mammosphere cultures.
|
|
| S4901 |
JNK-IN-8JNK-IN-8是第一个不可逆的JNK抑制剂，作用于JNK1，JNK2和JNK3，在A375细胞系中IC50分别为4.7 nM，18.7 nM和1 nM，比作用于MNK2，Fms选择性高10倍以上，对c-Kit， Met， PDGFRβ没有抑制作用。 |
SCC-9 cells were pre-treated with JNK inhibitor SP 600125 (1 umol/L) or JNK-IN-8 (1 umol/L) for 1 h, cells were also stimulated with indicated AZD8055 and cultured for 72 h, cell survival was analyzed. Scramble RNAi or JNK1/2 RNAi (JNK RNAi-1 or JNK RNAi-2, see methods) transfected HEK-293 cells were stimulated with AZD8055, cells were further cultured for 72 h before cell survival was tested. |
|
| S7508 |
JNK Inhibitor IXJNK inhibitor IX 是一种高度选择性JNK抑制剂，其作用于JNK2和JNK3的pIC50分别为6.5和6.7。 |
ICT induces JNK activation, mediating mPTP opening and CRC cell necrosis. JNK expression (p- and regular) in HT-29 or the primary CRC cells stimulated with applied ICT was tested by Western blots (a).
HT-29 cells were pre-treated with JNK inhibitors SP600125 (SP), JNK inhibitor IX (JNK-IX), and JNK-IN-8 (JNKi-8) (5 μM each) for 1 h, followed by ICT (25 μM) stimulation, MMP decrease was tested by
JC-10 dye assay (b, after 12 h), and cell necrosis was tested by LDH release assay (c, after 72 h).
|
|
| S8490 |
Tanzisertib(CC-930)CC-930对依赖于JNK的蛋白质底物c-Jun和JNK所有亚型的磷酸化具有ATP竞争性抑制作用(Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM)，选择性抑制ERK1和p38a的IC50分别为0.48 μM和3.4 μM。 |
||
| S8201 |
BI-78D3BI-78D3是一种竞争性的JNK抑制剂，IC50为280 nM，其选择性比对p38α高100倍，对mTOR和PI-3K没有活性。 |
||
| S7409 |
AnisomycinAnisomycin 是一种抗生素，抑制蛋白质合成，也是一种 JNK 激活剂。 |
Effect of TMZ (100 μmol/l for U87 cells, 50 μmol/l for U251 cells), anisomycin (4 μmol/l), SB203580 (10 μmol/l), TMZ+SB203580 (10 μmol/l) treatment on thephosphorylation of p38 and AQP4 for 24 h in U87 cells and U251 cells, detected by Western blotting. (A) Protein expression of p-p38, p38 and AQP4 in U87 cells with differenttreatments. (B) The ration of p-p38/p38 in U87 cells. (C) The proportion of AQP4 in GAPDH in U87 cells. (D) Protein expression of p-p38, p38 and AQP4 in U251 cells withdifferent treatments. (E) The ration of p-p38/p38 in U251 cells. (F) The proportion of AQP4 in GAPDH in U251 cells. *P< 0.05 versus the control group |
|
| S7637 |
DTP3DTP3是一种选择性GADD45β/MKK7抑制剂，能够抑制癌症选择性NF-κB存活途径。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1460 |
SP600125SP600125是一种广谱JNK抑制剂，作用于JNK1，JNK2和JNK3，无细胞试验中IC50分别为40 nM，40 nM和90 nM，比作用于MKK4选择性高10倍，比作用于MKK3， MKK6， PKB，和PKCα选择性高25倍，比作用于ERK2， p38， Chk1， EGFR等选择性高100倍。 |
Loss of DUSP4 function upregulates IL-6 and IL-8 and enhances mammosphere growth. Immunoblot analysis of MDA-231 cells after treatment of 24 hours with 1 umol/L selumetinib (MEKi) or 10 umol/L SP600125 (JNKi). I, MDA-231 mammosphere formation quantitated by GelCount software 7 days after siRNA transfection. Where indicated, selumetinib (MEKi) or SP600125 (JNK1) or the combination was added to the mammosphere cultures.
|
|
| S4901 |
JNK-IN-8JNK-IN-8是第一个不可逆的JNK抑制剂，作用于JNK1，JNK2和JNK3，在A375细胞系中IC50分别为4.7 nM，18.7 nM和1 nM，比作用于MNK2，Fms选择性高10倍以上，对c-Kit， Met， PDGFRβ没有抑制作用。 |
SCC-9 cells were pre-treated with JNK inhibitor SP 600125 (1 umol/L) or JNK-IN-8 (1 umol/L) for 1 h, cells were also stimulated with indicated AZD8055 and cultured for 72 h, cell survival was analyzed. Scramble RNAi or JNK1/2 RNAi (JNK RNAi-1 or JNK RNAi-2, see methods) transfected HEK-293 cells were stimulated with AZD8055, cells were further cultured for 72 h before cell survival was tested. |
|
| S7508 |
JNK Inhibitor IXJNK inhibitor IX 是一种高度选择性JNK抑制剂，其作用于JNK2和JNK3的pIC50分别为6.5和6.7。 |
ICT induces JNK activation, mediating mPTP opening and CRC cell necrosis. JNK expression (p- and regular) in HT-29 or the primary CRC cells stimulated with applied ICT was tested by Western blots (a).
HT-29 cells were pre-treated with JNK inhibitors SP600125 (SP), JNK inhibitor IX (JNK-IX), and JNK-IN-8 (JNKi-8) (5 μM each) for 1 h, followed by ICT (25 μM) stimulation, MMP decrease was tested by
JC-10 dye assay (b, after 12 h), and cell necrosis was tested by LDH release assay (c, after 72 h).
|
|
| S8490 |
Tanzisertib(CC-930)CC-930对依赖于JNK的蛋白质底物c-Jun和JNK所有亚型的磷酸化具有ATP竞争性抑制作用(Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM)，选择性抑制ERK1和p38a的IC50分别为0.48 μM和3.4 μM。 |
||
| S8201 |
BI-78D3BI-78D3是一种竞争性的JNK抑制剂，IC50为280 nM，其选择性比对p38α高100倍，对mTOR和PI-3K没有活性。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7409 |
AnisomycinAnisomycin 是一种抗生素，抑制蛋白质合成，也是一种 JNK 激活剂。 |
Effect of TMZ (100 μmol/l for U87 cells, 50 μmol/l for U251 cells), anisomycin (4 μmol/l), SB203580 (10 μmol/l), TMZ+SB203580 (10 μmol/l) treatment on thephosphorylation of p38 and AQP4 for 24 h in U87 cells and U251 cells, detected by Western blotting. (A) Protein expression of p-p38, p38 and AQP4 in U87 cells with differenttreatments. (B) The ration of p-p38/p38 in U87 cells. (C) The proportion of AQP4 in GAPDH in U87 cells. (D) Protein expression of p-p38, p38 and AQP4 in U251 cells withdifferent treatments. (E) The ration of p-p38/p38 in U251 cells. (F) The proportion of AQP4 in GAPDH in U251 cells. *P< 0.05 versus the control group |
|
| S7637 |
DTP3DTP3是一种选择性GADD45β/MKK7抑制剂，能够抑制癌症选择性NF-κB存活途径。 |
